The primary objective of the study is to evaluate the activity of BDD in subjects with acute
renal failure as measured by· reversal of acute renal failureSecondary objectives· tumor
response (complete and partial response)· To evaluate the safety of Bortezomib-
Doxorubicin-Dexamethasone in this patient population· to evaluate the activity of Bortezomib-
Doxorubicin -Dexamethasone on progression free survival · to evaluate the activity of
Bortezomib- Doxorubicin -Dexamethasone on overall survival